Eli Lilly and Company $LLY Shares Acquired by Personal CFO Solutions LLC

Personal CFO Solutions LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,466 shares of the company’s stock after purchasing an additional 289 shares during the quarter. Eli Lilly and Company comprises approximately 0.6% of Personal CFO Solutions LLC’s portfolio, making the stock its 23rd biggest position. Personal CFO Solutions LLC’s holdings in Eli Lilly and Company were worth $3,482,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. PNC Financial Services Group Inc. lifted its stake in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the period. Nuveen LLC purchased a new position in Eli Lilly and Company during the first quarter worth about $4,613,912,000. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Assenagon Asset Management S.A. lifted its position in Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after purchasing an additional 765,010 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Eli Lilly and Company by 13.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after purchasing an additional 682,203 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 0.6%

Eli Lilly and Company stock opened at $1,042.86 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,057.00. The firm has a market capitalization of $985.90 billion, a price-to-earnings ratio of 68.16, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The stock’s fifty day moving average is $849.83 and its two-hundred day moving average is $786.02. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LLY. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Tuesday. Scotiabank assumed coverage on Eli Lilly and Company in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price objective for the company. Morgan Stanley raised their target price on Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Guggenheim reaffirmed a “buy” rating and set a $948.00 price target on shares of Eli Lilly and Company in a research note on Thursday, October 16th. Finally, Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a research note on Monday, November 10th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,027.95.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.